Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4-5 chronic kidney disease

Research output: Contribution to journalEditorial

Original languageEnglish (US)
Article numberS13
JournalAnnals of Translational Medicine
Volume4
DOIs
StatePublished - Oct 1 2016

Fingerprint

Hepatitis C
Chronic Renal Insufficiency
Therapeutics
2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole
MK-5172

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{2923fd6582474765b329eb5cafddfcd8,
title = "Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4-5 chronic kidney disease",
author = "Bhamidimarri, {Kalyan R}",
year = "2016",
month = "10",
day = "1",
doi = "10.21037/atm.2016.10.41",
language = "English (US)",
volume = "4",
journal = "Annals of Translational Medicine",
issn = "2305-5839",
publisher = "AME Publishing Company",

}

TY - JOUR

T1 - Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4-5 chronic kidney disease

AU - Bhamidimarri, Kalyan R

PY - 2016/10/1

Y1 - 2016/10/1

UR - http://www.scopus.com/inward/record.url?scp=85011422076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011422076&partnerID=8YFLogxK

U2 - 10.21037/atm.2016.10.41

DO - 10.21037/atm.2016.10.41

M3 - Editorial

AN - SCOPUS:85011422076

VL - 4

JO - Annals of Translational Medicine

JF - Annals of Translational Medicine

SN - 2305-5839

M1 - S13

ER -